The FDA approved benralizumab (Fasenra) for adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

AstraZeneca's Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with ...

AstraZeneca’s FASENRA® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).1 EGPA is a rare, immune-mediated ...

More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.

AstraZeneca’s Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA), a rare immune-mediated vasculitis that can be fatal ...

AstraZeneca PLC (AZN, AZN.L) announced Wednesday that its Fasenra (benralizumab) has been approved in the US for the treatment of ...

The FDA has approved Fasenra® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.

The Phase III trial compared the efficacy of Fasenra with the standard treatment of GSK’s Nucala in patients with ...

EGPA, previously known as Churg-Strauss syndrome, is a rare inflammatory disorder characterized by asthma, necrotizing ...

New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids Dr. Michael Wechsler, Professor ...

AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated ...